

# Technical challenge of transfemoral aortic valve implantation in a patient with extreme femoral artery tortuosity – a case report

## Abstract

Transcatheter aortic valve implantation emerged as a less invasive procedure than surgical aortic valve replacement. Although the appropriate access site is chosen; vascular complications can not be avoided. Especially vascular complications are common with atherosclerotic iliac-femoral arteries.<sup>1-5</sup> In this article, we report a technically challenging transfemoral aortic valve implantation with extreme vascular calcification and tortuosity.

Volume 8 Issue 4 - 2017

**Erdem Karacop, Muharrem Nasifov, Baris Akdemir, Ahmet Bacaksiz, Omer Göktekin**  
Department of Cardiology, Bezmialem University, Istanbul, Turkey

**Correspondence:** Baris Akdemir, Department of Cardiology, Bezmialem University, Istanbul, Turkey, Tel 905065057654, Email barisakdemir75@hotmail.com

**Received:** March 18, 2017 | **Published:** March 30, 2017

## Introduction


Transcatheter aortic valve implantation (TAVI) has emerged as the current therapy of choice in patients with severe aortic valve stenosis who are not candidates for open heart surgery.<sup>6,7</sup> The common femoral artery is the most commonly used conduit for retrograde delivery of percutaneous aortic valves. Catheter-based angiography and contrast-enhanced CT images of the iliofemoral system is particularly useful for identifying the size (minimal luminal diameter), excessive tortuosity, circumferential calcification. Although the diameter of ilio-femoral axis is adequate, the diffuse atherosclerotic disease and excessive tortuosity create a serious obstacle to the TAVI procedure.<sup>8</sup> In the current case, we report for the first time using a snare from brachial approach to advance the tavi system from femoral and iliac arteries.

## Case report


A 82-year-old woman admitted to our institution for severe aortic stenosis. Past medical history included hypertension, chronic obstructive pulmonary disease and congestive heart failure. The patient was previously rejected for surgical aortic valve replacement because of high risk according to logistic Euroscore (31%) and STS (22%).

On physical examination she was symptomatic for dyspnea (NYHA class III). Midsystolic murmur was heard near midsternal border and pretibial edema was noted. Transthoracic echocardiography revealed dilatation of both atrium, left ventricular hypertrophy, moderate mitral regurgitation, severe tricuspid regurgitation and sclerosis of aortic valve with mean gradient 54 mmHg and maximal gradient 90 mmHg. Aortic valve planimetric area was calculated as 0,6 cm<sup>2</sup>. E<sub>f</sub>: 64% with pulmonary hypertension (PAPs 48 mmHg). Coronary angiography showed noncritical stenosis of coronary arteries. The decision was to perform transcatheter aortic valve implantation with transfemoral approach. A transvenous temporary pacing wire was positioned in the right ventricle via the left femoral vein. Percutaneous right femoral access was then obtained and 18 F delivery system was used. There were extreme calcification and tortuosity in femoral and iliac arteries (Figure 1 & 2). It was very difficult to advance the delivery system. Aggressive balloon angioplasty was performed with peripheral balloons

but no further advancement of the 18F system was possible. A 25 mm Amplatz Gooseneck snare was advanced from brachial artery to snare and prolapse through the sheath. This procedure allow additional tension, thereby allowing easy passage of the valve delivery system (Figure 3-5). Balloon valvuloplasty was performed before device placement, after which a 0,035 Amplatz extra stiff guidewire placed in the left ventricle. 25mm Direct Flow Medical valve is then advanced over a stiff guidewire and deployed within the aortic annulus. Prostar were used to close the vascular access site.



**Figure 1 & 2** Femoral and iliac arteries while performing transcatheter aortic valve implantation.



**Figure 3 & 4 & 5** A 25 mm Amplatz Gooseneck snare from brachial approach while capturing the wire.

## Discussion

Transcatheter aortic valve implantation has become widely accepted all over the world and tends to increase exponentially for years. Transfemoral access is less invasive and the most utilized way due to a number of advantages including shorter procedure and recovery times, less post-procedural pain and the ability to perform the procedure under conscious sedation. In a recent meta-analysis 30-day mortality was 4,7% with transfemoral approach and 8,1% with a non-transfemoral approach.<sup>9</sup> The 1- year mortality was 16,4% with transfemoral access and 24,8% with nontransfemoral access.<sup>9</sup> Nontransfemoral access is associated with worse outcomes compared with transfemoral access. Transfemoral access must be the first preferred route although there is a significant increase in vascular complications. Behind these complications the most common reason for failed procedure is the inability to ascend tavi system due to extreme vessel calcification and tortuosity. Special maneuvers can be applied to overcome this problem. Dandale et al postulated that using second wire from brachial approach to the left superficial femoral artery through a multipurpose catheter for additional support could be an option.<sup>9</sup> It was called 'railing track'. In the current case, we report for the first time in literature using a snare from brachial approach to advance the tavi system from femoral and iliac arteries. It has some advantages over the 'railing track'. Manipulation of two guidewires and using multipurpose catheters give additional risk for vascular complications. Using snare for additional tension can be an option for failed tavi procedures due to extreme femoral tortuosity and calcification.

## Acknowledgements

None.

## Conflicts of interest

Author declares there is no conflicts of interest.

## Funding

None.

## References

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2010;363(23):1597–1607.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. *N Engl J Med*. 2011;364(17):2187–2198.
3. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk. Acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol*. 2010;55(11):1080–1090.
4. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. *Circulation*. 2010;122(1):62–69.
5. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18F) CoreValve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *EuroIntervention*. 2008;4(2):242–249.
6. Thomas M. The global experience with percutaneous aortic valve replacement. *J Am Coll Cardiol Interv*. 2010;3(11):1103–1109.
7. Toggweiler S, Humphries KH, Lee M, et al. 5-Year outcome after transcatheter aortic valve implantation. *J Am Coll Cardiol*. 2013;61(4):413–419.
8. Dandale R, Zivelonghi C, Ribichini F. Trans-catheter aortic valve implantation in the catheterization laboratory: challenges and problem solving. *Cardioangiologia Intervencionista*. 2013;4:18–32.
9. Chandrasekhar J, Hibbert B, Ruel M, et al. Transfemoral vs Non-transfemoral access for transcatheter aortic valve implantation. *J Am Coll Cardiol*. 2015;31(12):1427–1438.